Vor Biopharma shares surge 13.01% after-hours following positive Phase 3 trial results for Telitacicept in IgA Nephropathy and Generalized Myasthenia Gravis.

Vor Biopharma surged 13.01% in after-hours trading, driven by positive clinical trial results for its drug Telitacicept in Phase 3 studies for IgA Nephropathy and Generalized Myasthenia Gravis, announced in late October and November. These outcomes demonstrated sustained efficacy and favorable safety profiles, bolstering investor confidence. Additionally, HC Wainwright’s October 30 price target increase to $52.00 and subsequent upgrades, despite earlier bearish catalysts like a $100M stock offering in early November, signaled renewed optimism. The recent after-hours rally aligns with the stock’s recovery from a 26% pre-market decline following the funding announcement, as clinical progress and analyst upgrades offset prior selling pressure.